es represent a $3.5 billion dollar market opportunity in the U.S alone. CR-BSI's and Blood Clots are two of the most severe patient issues plaguing the Healthcare System today thus positioning RyMed perfectly in the Marketplace. Two additional patents were issued to the company in the last 60 days, the most critical